Quick Answer
Petros Pharmaceuticals, Inc. reported Total Revenue of $5.99 million for the year ending 2022.
- Petros Pharmaceuticals, Inc. showed a decrease of -23.3% in Total Revenue from 2021 to 2022.
- This data is from Petros Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2023.
- XBRL data for this metric is available from 2020 to 2022 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $1.79 million | Q2 2020: $1.37 million | Q3 2020: $3.46 million | Q1 2021: $4.08 million | Q2 2021: $2.46 million | Q3 2021: $2.15 million | Q1 2022: $2.47 million | Q2 2022: $4.19 million | Q1 2023: $2.52 million | Q2 2023: $1.99 million.
- Over the full 3 years of available data (2020 to 2022), Petros Pharmaceuticals, Inc.'s Total Revenue has declined by 37.3%.
- Historical annual values: Fiscal year 2022: $5.99 million | Fiscal year 2021: $7.81 million | Fiscal year 2020: $9.56 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: